Bamco Inc. NY reduced its holdings in Repligen Co. (NASDAQ:RGEN - Free Report) by 3.2% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 167,019 shares of the biotechnology company's stock after selling 5,495 shares during the period. Bamco Inc. NY owned approximately 0.30% of Repligen worth $24,856,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds have also recently made changes to their positions in the company. Lazard Asset Management LLC lifted its stake in Repligen by 206.1% in the first quarter. Lazard Asset Management LLC now owns 202 shares of the biotechnology company's stock worth $36,000 after purchasing an additional 136 shares during the last quarter. B. Riley Wealth Advisors Inc. boosted its stake in shares of Repligen by 12.6% during the first quarter. B. Riley Wealth Advisors Inc. now owns 1,450 shares of the biotechnology company's stock valued at $267,000 after purchasing an additional 162 shares during the period. Tidal Investments LLC increased its stake in Repligen by 11.6% in the 1st quarter. Tidal Investments LLC now owns 1,421 shares of the biotechnology company's stock worth $261,000 after buying an additional 148 shares during the period. Virtu Financial LLC lifted its holdings in Repligen by 29.3% during the 1st quarter. Virtu Financial LLC now owns 1,545 shares of the biotechnology company's stock valued at $284,000 after buying an additional 350 shares in the last quarter. Finally, GAMMA Investing LLC boosted its position in Repligen by 183.4% in the 2nd quarter. GAMMA Investing LLC now owns 479 shares of the biotechnology company's stock valued at $60,000 after buying an additional 310 shares during the period. 97.64% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Ratings Changes
Several analysts have recently weighed in on the stock. Benchmark reaffirmed a "hold" rating on shares of Repligen in a research note on Monday, August 5th. Wolfe Research started coverage on Repligen in a report on Thursday, November 14th. They issued a "peer perform" rating for the company. Royal Bank of Canada reissued an "outperform" rating and set a $205.00 target price on shares of Repligen in a research report on Thursday, September 26th. Wells Fargo & Company assumed coverage on shares of Repligen in a research report on Tuesday, August 27th. They issued an "overweight" rating and a $180.00 price target for the company. Finally, StockNews.com raised shares of Repligen from a "sell" rating to a "hold" rating in a report on Friday, November 22nd. Four analysts have rated the stock with a hold rating and eight have given a buy rating to the company's stock. According to MarketBeat.com, Repligen currently has a consensus rating of "Moderate Buy" and a consensus target price of $190.25.
Check Out Our Latest Stock Report on RGEN
Repligen Trading Down 2.5 %
Shares of RGEN stock traded down $3.71 on Tuesday, hitting $146.75. The company had a trading volume of 123,004 shares, compared to its average volume of 661,773. Repligen Co. has a twelve month low of $113.50 and a twelve month high of $211.13. The company has a 50-day moving average price of $141.18 and a 200-day moving average price of $142.27. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44.
Repligen (NASDAQ:RGEN - Get Free Report) last posted its earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share for the quarter, beating the consensus estimate of $0.34 by $0.09. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. The firm had revenue of $154.87 million during the quarter, compared to analyst estimates of $153.34 million. During the same period in the previous year, the firm earned $0.23 EPS. The business's quarterly revenue was up 9.7% on a year-over-year basis. Sell-side analysts predict that Repligen Co. will post 1.52 earnings per share for the current fiscal year.
Insiders Place Their Bets
In other news, Director Anthony Hunt sold 22,191 shares of Repligen stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $145.37, for a total value of $3,225,905.67. Following the sale, the director now owns 139,840 shares in the company, valued at $20,328,540.80. This trade represents a 13.70 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 1.20% of the stock is currently owned by company insiders.
About Repligen
(
Free Report)
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.
Featured Stories
Before you consider Repligen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Repligen wasn't on the list.
While Repligen currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
